×

BioMark Diagnostics to Present at Rodman & Renshaw Global Investment Conference

VANCOUVER, British Columbia, Sept. 3, 2015 (GLOBE NEWSWIRE) -- BioMark Diagnostics Inc. ("BioMark") (CSE:BUX) (FSE:20B) (OTCQB:BMKDF) announces that President and CEO Rashid Ahmed will present a company overview at the Rodman & Renshaw 17th Annual Global Investment Conference on Wednesday, September 9, 2015, at 10:50 a.m. Eastern time (7:50 a.m. Pacific time). The conference is being held at the St. Regis Hotel in New York City.

"We are excited about the opportunity to increase visibility for our ultra-early oncology diagnostic technology with leading U.S. institutional investors attending this premier biotechnology conference," said Mr. Ahmed. "We understand the importance of having a strong operating presence in the U.S. and we are committing resources to successfully execute on the U.S. strategy we recently unveiled."

A webcast of the presentation will be available at www.biomarkdiagnostics.com/investor-relations/corporate-presentations-and-updates/. A replay of the webcast will be available following the presentation.

About BioMark Diagnostics Inc.

BioMark Diagnostics is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. More information is available at www.biomarkdiagnostics.com.

Further information about BioMark Diagnostics is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

The CSE has not reviewed, approved or disapproved the content of this press release.

CONTACT: Company Contact Rashid Ahmed Bux President & CEO BioMark Diagnostics Inc. 604-282-6567 info@biomarkdiagnostics.com Investor Contact LHA Jody Cain 310-691-7100 Jcain@lhai.comSource:BioMark Diagnostics Inc.